/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Kodiak Sciences Inc Share Price Today: Live Updates & Key Insights

Kodiak Sciences Inc share price today is $23.518, up -3.06%. The stock opened at $23.48 against the previous close of $24.54, with an intraday high of $24.31 and low of $22.8.

Kodiak Sciences Inc Share Price Chart

style
pb-0

Kodiak Sciences Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Kodiak Sciences Inc Share Price Performance

$23.518 -0.0306(-3.06%) KOD at 13 Mar 2026 01:53 PM Biotechnology
Lowest Today 22.8
Highest Today 24.31
Today’s Open 23.48
Prev. Close 24.54
52 Week High 31.18
52 Week Low 1.92
Day’s Range: Low 22.8 High 24.31
52-Week Range: Low 1.92 High 31.18
1 day return -
1 Week return -4.34
1 month return +7.84
3 month return +3.34
6 month return +154.71
1 year return +591.56
3 year return +303.22
5 year return -81.37
10 year return -

Kodiak Sciences Inc Institutional Holdings

Baker Bros Advisors LP 32.63

BlackRock Inc 4.84

Point72 Asset Management, L.P. 4.65

Vanguard Group Inc 3.79

BRAIDWELL LP 3.40

RTW INVESTMENTS, LLC 2.44

ICONIQ Capital, LLC 2.07

Vanguard Total Stock Mkt Idx Inv 2.01

TCG Crossover Management, LLC 1.88

Boxer Capital Management, LLC 1.86

SILVERARC CAPITAL MANAGEMENT, LLC 1.68

State Street® SPDR® S&P® Biotech ETF 1.61

Acadian Asset Management LLC 1.59

Artisan Partners Limited Partnership 1.37

State Street Corp 1.36

Geode Capital Management, LLC 1.31

iShares Russell 2000 ETF 1.31

Adage Capital Partners Gp LLC 1.29

Board of Ttees Leland Stanford Jr Univ 1.13

Morgan Stanley - Brokerage Accounts 1.06

Perceptive Advisors LLC 1.04

Artisan International Small-Mid Investor 0.85

Artisan Non-U.S. Small-Mid Growth Comp 0.85

BOONE CAPITAL MANAGEMENT LLC 0.83

T. Rowe Price Associates, Inc. 0.82

Vanguard Institutional Extnd Mkt Idx Tr 0.70

iShares Biotechnology ETF 0.69

Fidelity Small Cap Index 0.53

iShares Russell 2000 Value ETF 0.47

Federated Hermes MDT SCC Institutional 0.40

Federated Hermes MDT Small Cap Core IS 0.40

State St Russell Sm/Mid Cp® Indx SL Cl I 0.37

T. Rowe Price Small-Cap Value 0.37

Fidelity Extended Market Index 0.34

Invesco Dorsey Wright SmallCap Momt ETF 0.32

Fidelity Enhanced Small Cap ETF 0.32

Schwab US Small-Cap ETF™ 0.31

BlackRock Health Sciences Opps Inv A 0.31

T. Rowe Price US Small-Cap Core Equity 0.30

T. Rowe Price Small-Cap Stock 0.30

Kodiak Sciences Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 2

Sell: 3

Strong Sell: 0

Kodiak Sciences Inc Fundamentals

Market Cap 1498.13 M

PB Ratio 63.2335

PE Ratio 0.0

Enterprise Value 1488.29 M

Total Assets 335.58 M

Volume 599072

Kodiak Sciences Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-271423000 -271.4M, FY22:339738177000 339738.2M, FY21:-258086000 -258.1M, FY20:-128947000 -128.9M, FY19:-46727000 -46.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-6539000 -6.5M, Q2/2025:-6538000 -6.5M, Q1/2025:-6728000 -6.7M, Q3/2024:null 0.0M, Q2/2024:-6681000 -6.7M

Quarterly Net worth Q3/2025:-61457000 -61.5M, Q2/2025:-54313000 -54.3M, Q1/2025:-57461000 -57.5M, Q3/2024:-43946000 -43.9M, Q2/2024:-45117000 -45.1M

About Kodiak Sciences Inc & investment objective

Company Information Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Organisation Biotechnology

Employees 123

Industry Biotechnology

CEO Dr. Victor Perlroth M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow